Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Repligen CorporationNASDAQ: RGEN

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns positive

Q2 FY2026 accounts payables was $194K, compared with -$1.58M a year earlier. Trailing-twelve-month accounts payables was $10.24M. Over 3 fiscal years it compounded at -20.3% a year.

Context

  • Accounts payables amounted to 0.6% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $194K or moves back toward the trailing-twelve-month quarterly average of $2.56M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$194K-96.7% QoQ
Last fiscal yearDec 2025
-$4.15M-132.2% YoY
LTMJun 2026
$10.24M+233.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+112.2%——
1 year-132.2%——
3-year CAGR-20.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(4.15M) USD
Year-over-year change
-132.2%

Accounts Payables vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 accounts payables of $10.24M is the 5th largest of the 9 companies compared; the peer median is $474K.
  • Its year-over-year change of +233.1% is the 3rd highest of 9, against a peer median of +5.3%.
  • Accounts payables amounts to 1.3% of revenue for RGEN, versus a peer median of 0.8%.
RGEN Competitors Peer median
Accounts Payables for RGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$70M +483.3%-49.1%0.9%
AVTRAvantor, Inc.LTM Jun 2026$41M +25.0%+39.6%0.6%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$34.6M +142.0%-89.8%1.3%
TECHBio-Techne CorporationLTM Sep 2026$24.54M +575.7%—2.0%
RGENRepligen CorporationLTM Jun 2026$10.24M +233.1%-20.3%1.3%
QGENQiagen N.V.LTM Jun 2026$1.56M -130.5%+68.6%0.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$1.15M -14.3%+67.0%0.6%
BLFSBioLife Solutions, Inc.LTM Mar 2026$948K -17.9%—1.0%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$0 -100.0%-13.4%0.0%
Peer median (excluding RGEN) $474K+5.3%+13.1%0.8%

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income128.29M185.96M41.58M(25.51M)48.89M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
Deferred Income Tax6.52M(1.35M)2.32M(16.79M)(3.37M)
Stock-Based Compensation27.5M27.32M25.58M48.07M32.61M
Change in Working Capital(102.13M)(69.84M)(8.64M)60.92M(50.88M)
Accounts Receivables(46.53M)(3.6M)(3.31M)(14.03M)(17.17M)
Inventory(89.78M)(57.2M)40.97M56.9M(14.95M)
Accounts Payables19.52M(8.2M)(9.8M)12.9M(4.15M)
Other Working Capital14.66M(841K)(36.5M)5.16M(14.62M)
Other Non-Cash Items20.39M(27.01M)(33.03M)22.15M(6.79M)
Operating Cash Flow119.02M172.08M113.92M175.39M117.42M
Capital Expenditures(67.09M)(133.35M)(38.99M)(32.91M)(23.52M)
Acquisitions (Net)(149.89M)0(186.64M)(54.77M)(70.33M)
Purchases of Investments0(100M)00(200.26M)
Sales of Investments00102.32M00
Other Investing Activities(4.19M)(48.4M)(2.73M)(5.94M)(4.37M)
Investing Cash Flow(221.17M)(233.24M)(123.28M)(86.38M)(298.47M)
Debt Repayment(21K)0290.09M(69.94M)0
Common Stock Issued3.88M3.71M1.08M4.29M3.18M
Common Stock Repurchased00(14.39M)00
Dividends Paid00000
Other Financing Activities(2.9M)(17.04M)(27.82M)(17.26M)(18.38M)
Financing Cash Flow961K(13.34M)248.96M(82.9M)(15.21M)
Effect of Forex Changes(12.29M)(5.87M)(11.74M)(77K)4.93M
Net Change in Cash(113.48M)(80.36M)227.87M6.03M(191.33M)
Free Cash Flow51.93M38.74M74.93M142.49M93.9M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.